Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma
Authors:
- Daphne AngDADaphne Ang
- Andre L. MoreiraAMAndre L. Moreira
- Maureen F. ZakowskiMZMaureen F. Zakowski
- 1 August 2012
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 77 (2) , 299-305
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor TherapyJournal of Clinical Oncology, 2011
- Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African AmericansJournal of Thoracic Oncology, 2011
- Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancerJournal of Translational Medicine, 2010
- Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor MutationsJournal of Thoracic Oncology, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung CancerClinical Cancer Research, 2009
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004